A pilot study of thiamine and folic acid in hemodialysis patients with cognitive impairment

Renhua Lu
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
https://orcid.org/0000-0003-3555-505X

Yan Fang
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Yijun Zhou
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Miaolin Che
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Jianxiao Shen
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Qian Liu
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Haifen Zhang
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Shuting Pan
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Yan Lin
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Qin Wang
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Shan Mou
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Zhaohui Ni
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Leyi Gu (✉ guleyi@aliyun.com)
https://orcid.org/0000-0003-4358-0132

Research article

Keywords: End-stage renal disease; Cognitive function; Vitamins B; Oxidative stress; Survival

DOI: https://doi.org/10.21203/rs.3.rs-30331/v2
Abstract

Background: This study aimed to explore the effectiveness of thiamine and folic acid supplementation on the improvement of the cognitive function in patients with maintenance hemodialysis.

Methods: In the present study, we randomly assigned patients undergoing hemodialysis who had the Montreal Cognitive Assessment (MoCA) score lower than 26 to treatment group (n=25, thiamine 90mg/day combined with folic acid 30mg/day) or control group (n=25, nonintervention). All subjects were followed up for 96 weeks. The primary outcome was the improvement of the MoCA score. The secondary outcomes included homocysteine level, survival and safety.

Results: Patients in treatment group had an increase of the MoCA score from 21.95±3.81 at baseline to 25.68±1.96 at week 96 (P<0.001, primary outcome), as compared with the MoCA score from 20.69±3.40 to 19.62±3.58 in control group. Thiamine combined with folic acid treatment also resulted in lower level of serum homocysteine in treatment group compare with control group at week 96 (P<0.05, secondary outcome). 3 patients and 9 patients died during follow-up period in treatment and control group respectively (P=0.048). The proportion of adverse events in treatment group was significantly lower than that in control group.

Conclusion: Hemodialysis patients with cognitive impairment treated with thiamine and folic acid had a significant improvement in MoCA score.

Trial registration: Clinical trial registration number: ChiCTR-IPR-17012210.

Background

End Stage Renal Disease (ESRD) is a public health issue of global concern. United States Renal Data System (USRDS) reported that the overall prevalence of ESRD in 2018 is 1,943 per million people in the United States[1]. The number of dialysis patients in Asia is expected to rise to 2.162 million by 2030[2]. Cognitive Impairment (CI) is one of the common neurological complications in patients with ESRD[3]. Our previous single-center cohort observational study showed that the incidence of CI in patients with maintenance hemodialysis (MHD) was 51.6% and 3 times higher than that of non-Kidney disease patients[4]. MoCA score which has been confirmed in the previous literature[5,6] was used to determine cognitive impairment in MHD patients in this study. Furthermore, the 3-year survival rate of MHD patients with CI was significantly lower than that of patients with normal cognitive function[4].

An association between cognitive dysfunction and oxidative stress has been discussed[3]. Animal studies demonstrated that the cognitive function of ESRD mice which was assessed by the radial arm water maze test decreased compared with the sham-operated control mice. Furthermore, treatment with tempol (an antioxidant) in ESRD mice improved cognitive function compared to treatment with vehicle. Histological assessment suggested indicated increased oxidation in the hippocampal neurons.
and increased numbers of neurons undergoing apoptosis or necrosis, compared to control mice and those treated with tempol [7].

Recently, studies have found that thiamine, as a cofactor of transferenolase, plays an important role in reducing the production of reactive oxygen species (ROS) in the nervous system and reducing oxidative stress [8, 9]. Folic acid has a direct antioxidant effect, which interacts with enzyme endothelial nitric oxide synthase (eNOS) and affects the bioavailability of nitric oxide cofactor [10]. Moreover, recent animal study have also found that oxidative stress index including malondialdehyde (MAD), protein carbonyl, 8-hydroxydeoxyguanosine (8-OHdG) and nitric oxide (NO) were closely related to thiamine and folic acid deficiency, leading to oxidative stress and cognitive impairment [11]. Clinical studies showed that both thiamine and folic acid supplementation can reduce the level of oxidative stress index including homocysteine in blood [10, 12], thereby reducing oxidative stress and bringing benefits to the treatment of cardiovascular complications in MHD patients [12], particularly in those intensive treatment or with a drop in homocysteine levels of more than 20 percent [12]. However, recent systematic review and Meta-Analysis indicated that thiamine or folic acid alone can not improves cognitive function healthy older people [13, 14]. Therefore, we designed this pilot study to explore whether the intensive combination of these two vitamin B can improve cognitive function in MHD patients with CI. The dose of thiamine: 90mg/d is refer to the treatment dose of Wernicke's encephalopathy [15] and refeeding syndrome [16]. The dose of folic acid: 30mg/d is according to the treatment of cardiovascular complications in MHD patients [12].

The present study conducted a randomized controlled pilot study to explore whether patients on MHD with CI can improve their MoCA score and survival by thiamine combined with folic acid.

Methods

Study design and participant

This study was designed as a randomized, controlled, single-center study. Eligible patients were adults (18-80 years of age) with end-stage kidney disease who had been undergoing hemodialysis for at least three months and who had cognitive impairment (the MoCA score lower than 26 and <25 if the patients get education less than 12 years) [5]. The detail inclusion and exclusion criteria were showed in the Supplemental Figure 1. MoCA [6] was evaluated by professional neurologists to assess cognitive ability. Every participant completed the MoCA test before or during the first hour of haemodialysis at baseline, week 48 and week 96.

Randomization

Randomization sequence was generated by an independent data manager using SAS (version 9.3) and stored within sealed opaque envelopes. The study physician opened an envelope to obtain the treatment assignment every time a patient was consented to enter the trial. Assignments were balanced in a 1:1 ratio between the two groups. No masking was applied.
Data collection

Hemodialysis patients in Renji Hospital, School of Medicine, Shanghai Jiao Tong University were screened. Eligible patients assigned to treatment group received thiamine 90mg/day combined with folic acid 30mg/day for 96 weeks, and those assigned to control group had nonintervention. Concomitant treatment with stable doses of anticoagulant medicine, antihypertension medicine, hypoglycemic medicine and statins. The initiation of new improved cognitive medicine was prohibited. The subjects who signed the informed consent were grouped by the investigator according to the treatment allocation.

During the 96-weeks intervention period, urine volume and the following information of hemodialysis treatment was recorded: average weekly ultrafiltration (L/session), intradialytic hypotension (The definition of intradialytic hypotension is systolic pressure <90 mmHg or diastolic pressure <60 mmHg, accompanied by dizziness and other symptoms of hypotension during dialysis treatment within one week prior to follow-up), body weight of pre and post haemodialysis, blood pressure (BP) of pre and post haemodialysis.

Efficacy Outcomes

The primary outcome was the mean change from baseline at week 96 in the MoCA scores. The secondary outcomes included the mean change of serum homocysteine from baseline to week 96, survival and safety during follow-up.

Estimated the serum thiamine, folic acid and homocysteine

Vitamin detector LINBIAO LK3000VI (Tianjin lanbiao electronic technology development co., LTD. China) and the original matching thiamine content determination kit were used to detect serum thiamine levels of two groups. Beckman Coulter's UniCel Dxl 800 Access Immunoassay System (Beckman Coulter, inc., United States) and the original folic acid assay kit were used to detect serum folic acid levels of two groups by immunoluminescence assay. The Hitachi 7600-020 automatic biochemical analyzer (Hitachi, Japan) and the corresponding homocysteine assay kit (Ningbo meicang biotechnology co., LTD. China) were used to detect serum homocysteine levels.

Statistical analyses

The primary analysis only included patients with completed primary outcomes. The comparisons among MoCA scores and other secondary outcomes over time within subjects was conducted by using repeated measure ANOVA, and pairwise t-test with Bonferroni adjustment was performed for multiple comparisons. On the other hand, for comparisons between treatment and control group, simple one-way ANOVA or Wilcoxon rank sum test was used. The chisquare method was used for statistical analysis of the categorical data. For missing data in secondary efficacy outcomes, they were assumed to be missing at random and multiple imputation was conducted. Kaplan-Meier survival curve was used for survival analysis.
Variables of normal distribution were presented by means with SD while skewed ones were reported as the median and the inter-quartile ranges. Counting data were expressed as constituent ratios or percentages.

A p < 0.05 was considered statistically significant difference. Statistical analyses were conducted with SPSS (Version 20.0, SPSS Inc., Chicago, IL, USA).

**Results**

**Baseline characteristics of patients**

A total of 50 patients with MHD met the inclusion criteria and included in the present study. According to the study protocol, subjects were randomly divided 1:1 into treatment group (n=25) and control group (n=25) (Supplemental Figure 1).

There was no significant difference in demographic data, medical history and hemodialysis data between treatment group and control group except ultrafiltration volume (P=0.039; Table 1, Supplemental Table 1). Comparing the laboratory test, there was no significant difference except PH, bicarbonate, transferrin saturation (TAST), ferritin and Phosphorus (P<0.05; Table 1, Supplemental Table 1). There was no significant difference in MoCA score between treatment group and control group (P=0.076; Table 1).

**Table 1. Comparison of baseline data between the treatment group and the control group**
|                                | Treatment group (n=25) | Control group (n=25) | P value |
|--------------------------------|------------------------|----------------------|---------|
| Age, years                     | 66.16±7.61             | 69.00±10.80          | 0.287   |
| Male, n (%)                    | 18(72)                 | 19(76)               | 0.747   |
| History of smoking, n (%)      | 14(56)                 | 12(48)               | 0.571   |
| History of alcoholism, n (%)   | 11(44)                 | 7(28)                | 0.239   |
| History of drug abuse, n (%)   | 2(8)                   | 0(0)                 | 0.470   |
| Education status (≥12 years, n [%]) | 11(44)                 | 14(56)               | 0.369   |
| Family history of CI, n(%)     | 1(4)                   | 0(0)                 | 1.000   |
| Primary cause of MHD, n (%)    |                        |                      |         |
| Primary glomerulonephritis     | 5(20)                  | 7(28)                | 0.508   |
| Diabetic nephropathy           | 5(20)                  | 1(4)                 | 0.192   |
| Hypertensive nephrosclerosis   | 3(12)                  | 6(24)                | 0.462   |
| ADPKD                          | 1(4)                   | 1(4)                 | 1.000   |
| Others                         | 3(12)                  | 2(8)                 | 1.000   |
| Unknown cause                  | 8(32)                  | 8(32)                | 1.000   |
| Complication, n (%)            |                        |                      |         |
| Hypertension                   | 24(96)                 | 23(92)               | 1.000   |
| Diabetes                       | 9(36)                  | 5(20)                | 0.208   |
| Cardiovascular disease         | 8(32)                  | 5(20)                | 0.333   |
| Cerebrovascular disease        | 5(20)                  | 4(16)                | 1.000   |
| Cirrhosis                      | 0(0)                   | 0(0)                 | 1.000   |
| Chronic obstructive pulmonary disease | 1(4)                   | 0(0)                 | 1.000   |
| Urine, mL/day                  | 0(0,150)               | 0(0,0)               | 0.230   |
| Dialysis vintage, months       | 82.60±51.90            | 107.40±72.40         | 0.169   |
| Dialysis duration (h/session)  | 4.00±0.00              | 4.02±0.10            | 0.322   |
| Dialysis frequencies (time/week) | 2.96±0.20              | 2.92±0.28            | 0.561   |
| Intradialytic hypotension (patients, %) | 13(52)                 | 12(48)               | 0.777   |
| Hb (g/L)                       | 113.63±15.54           | 112.59±13.53         | 0.812   |
| ALT (U/L)                      | 11.13±4.53             | 14.03±7.97           | 0.131   |
| AST (U/L)                      | 12.42±4.45             | 15.86±6.89           | 0.054   |
| TP (g/L)                       | 72.14±6.21             | 71.71±5.02           | 0.797   |
| Alb (g/L)                      | 39.97±2.02             | 39.47±3.06           | 0.514   |
| PH                             | 7.28±0.05              | 7.33±0.04            | 0.000   |
| HCO₃⁻ (mmol/L)                 | 18.39±2.41             | 20.28±2.23           | 0.009   |
| K⁺ (mmol/L)                    | 4.76±0.86              | 4.50±0.56            | 0.222   |
| Na⁺ (mmol/L)                   | 136.92±3.30            | 136.82±3.62          | 0.923   |
| Calcium (mmol/L)               | 2.25±0.24              | 2.32±0.21            | 0.293   |
Phosphorus (mmol/L)  | 2.08±0.63 | 1.57±0.51 | 0.005
Cholesterol (mmol/L) | 4.09±0.96 | 3.83±1.01 | 0.379
Triglyceride (mmol/L) | 2.31±1.39 | 2.07±1.32 | 0.550
iPTH (pg/ml)          | 303.00±212.08 | 215.04±179.15 | 0.141
Glucose (mmol/L)      | 6.15±2.27 | 5.69±52.27 | 0.496
CRP (mg/dl)           | 2.32±1.12±5.13 | 4.26±1.77±7.77 | 0.094
β2-MG (mg/L)          | 10.25±7.58±12.05 | 12.00±8.20±43.40 | 0.385
BNP pg/ml             | 219.50±95.25±375.00 | 198.50±100.00±383.00 | 0.809
sPkt/V                | 1.58±0.25 | 1.69±0.11 | 0.063
Thiamine (nmol/L)     | 53.29±7.12 | 52.79±8.57 | 0.831
folic acid (ng/mL)    | 7.96±2.10 | 8.77±4.05 | 0.389
Homocysteine (umol/L) | 43.92±21.05 | 46.82±23.79 | 0.663
MoCA                  | 22.08±3.59 | 20.12±4.02 | 0.076

Notes: The definition of drug abuse is drug dependence, no matter how much, such as sleeping pills.

Primary analysis

MoCA scores at week 96 in treatment group and control group were 25.68±1.96 and 19.63±3.58 (P<0.05; Table 2). In addition, MoCA scores increased significantly from baseline to 96 weeks in treatment group, but not control group (Table 2). The proportion of patients with MoCA scores greater than or equal to 26 was significantly higher in treatment group than that in control group at week 96 (72.7% vs 6.2%, P<0.001; Supplemental Table 2).

Seven items of MoCA score were compared between the treatment group at baseline and the 96 weeks of follow-up. We found that the item of abstraction and delayed recall were improved by thiamine and folic acid treatment significantly (Supplemental Table 3).

Secondary analysis

At 96 weeks of follow-up, the level of serum homocysteine in treatment group and control group were 32.58±13.42 μmol/L and 45.69±18.54 μmol/L, P=0.016. We also found that the levels of serum thiamine and folic acid in treatment group were significantly higher than those in control group (Table 2).

In addition, the level of folic acid, but not serum thiamine or homocysteine had significantly changed over time in treatment group (Table 2).

There was no significant difference in hemodialysis data and laboratory test between treatment group and control group at 48 weeks or 96 weeks of follow-up (Supplemental Table 4 and Supplemental Table 5).
Table 2. Comparison of MoCA scores, serum thiamine, folic acid and homocysteine in the control and treatment group at baseline and week 96

|                  | Treatment group (n=22) | Control group (n=16) | p-value |
|------------------|------------------------|----------------------|---------|
| **MoCA**         |                        |                      |         |
| Baseline         | 21.95±3.81             | 20.69±3.40           | 0.297   |
| 48 weeks         | 25.68±2.40             | 20.00±3.95           | <0.001  |
| 96 weeks         | 25.68±1.96             | 19.63±3.58           | <0.001  |
| Comparison between 96 weeks and baseline, P value | <0.001 | 0.657 |
| Treatment difference over time, P value | <0.001 | 0.304 |
| **Thiamine (nmol/L)** |                        |                      |         |
| Baseline         | 53.63±7.33             | 51.98±10.13          | 0.563   |
| 48 weeks         | 57.79±6.09             | 54.90±6.28           | 0.163   |
| 96 weeks         | 57.60±5.86             | 52.87±4.45           | 0.011   |
| Comparison between 96 weeks and baseline, P value | 0.168 | 1.000 |
| Treatment difference over time, P value | 0.063 | 0.499 |
| **Folic acid (ng/mL)** |                        |                      |         |
| Baseline         | 7.88±2.18              | 8.39±2.63            | 0.519   |
| 48 weeks         | 21.94±4.85             | 8.09±4.62            | <0.001  |
| 96 weeks         | 18.35±7.94             | 7.3±4.83             | <0.001  |
| Comparison between 96 weeks and baseline, P value | <0.001 | 0.870 |
| Treatment difference over time, P value | <0.001 | 0.719 |
| **Homocysteine (umol/L)** |                        |                      |         |
| Baseline         | 43.55±21.81            | 48.72±27.43          | 0.522   |
| 48 weeks         | 33.64±13.04            | 41.36±13.34          | 0.083   |
| 96 weeks         | 32.58±13.42            | 45.69±18.54          | 0.016   |
| Comparison between 96 weeks and baseline, P value | 0.111 | 1.000 |
| Treatment difference over time, P value | 0.063 | 0.594 |

Notes: The normal range for blood thiamine concentration is approximately 70-180nmol/L [17] and the normal range for serum levels of folate acid is approximately 2.7-17ng/ml [18] in the general population.

A total of 12 patients died during a follow-up of 96 weeks. The mortality rate in treatment group and control group was 12.0% and 36.0%, P=0.047. The Kaplan-Meier survival curve analysis showed that the survival rate of treatment group was lower than that of control group (P=0.048; Figure 1). The causes of
death were cardiovascular and cerebrovascular diseases (9 cases, 75.0%), malignant tumors (2 cases, 16.7%), and infection (1 case, 8.3%) (Table 3).

| Table 3. Comparison of major causes of death between treatment group and control group |
|---------------------------------|-----------------|
| cardiovascular and cerebrovascular events (n, %) | Treatment group\(n=3\) | Control group\(n=9\) |
| malignant tumor (n,%)) | 1\(\times\)33.3\% | 8\(\times\)88.9\% |
| Infection (n, %) | 0\(\times\)0% | 1\(\times\)11.1\% |

There were 33 (66%) adverse events (AE) occurred during follow-up period. In treatment group, there were 7 events (21.2%), including 3 malignant tumor, 2 cardiovascular and cerebrovascular events, 1 heart failure and 1 hypotension. In control group, there were 26 AE (78.8%), including 12 cardiovascular and cerebrovascular events, 3 heart failure, 3 infection, 3 internal fistula dysfunction, 2 upper gastrointestinal bleeding and 1 hypotension. The proportion of AE in control group was significantly higher than that in treatment group (P=0.000). Among them, cardiovascular and cerebrovascular events in treatment group were significantly lower than those in control group (P=0.005).

**Discussion**

In the present pilot study, we found that the MoCA score of treatment group was significantly improved, implicating that supplementation with thiamine and folic acid may improve the cognitive function of patients undergoing MHD with CI. The survival of patients in treatment group was significantly improved compared with that in control group. The proportion of adverse events in the control group was significantly higher than that in the treatment group, especially in cardiovascular and cerebrovascular events.

The present study pointed out that after 96 weeks of thiamine (90mg/day) and folic acid (30mg/day) supplementation, the MoCA score of the treatment group were significantly higher than that of control group, implicating the improvement of cognitive function. Recently, an animal study in mice demonstrated that thiamine deficiency decreased activity of antioxidants and increased activity of malondialdehyde (MAD), protein carbonyl, 8-hydroxydeoxyguanosine (8-OHdG) and nitric oxide (NO) in the cerebral cortex and hippocampus, leading to oxidative stress and cognitive impairment [11]. Meanwhile, an experimental mouse model simulating the effects of exposure to methotrexate on behavior and cognitive function found acute decrease in serum and CSF levels of folate acid, leading to oxidative stress and displayed cognitive [19]. This may be due to thiamine, as a cofactor of ketolase, can act as an oxygen free radical scavenger and play an important role in reducing the production of reactive oxygen species (ROS) in the nervous system and alleviating oxidative stress [11]. Another reason is the direct antioxidant effect of folic acid, which interacts with endothelial nitric oxide synthase (eNOS) to affect the bioavailability of NO cofactors. Moreover, folic acid is essential for the metabolism of homocysteine into methionine, which can reduce the homocysteine level of MHD patients, thus relieving
oxidative stress. However, there is insufficient evidence to support supplementation with thiamine or folic acid alone can improve cognitive functioning in healthy older people or non-chronic kidney diseases (CKD) older adults. Therefore, we designed this pilot study to explore whether the combination of these two vitamin B can improve cognitive function in MHD patients with CI.

Furthermore, the normal range for blood thiamine concentration is approximately 70-180nmol/L in the general population. However, in MHD patients, the level of blood thiamine concentration is lower than general population which has been founded in our study. Because thiamine is a water-soluble vitamin, the absorption is affected by uremia toxins. Moreover, it will be cleared by dialysis, especially in patients receiving high-flux dialysis. After 96 weeks of thiamine supplementation, blood thiamine concentration rose, but did not reach the normal range, which may be related to the decreased expression of thiamine transporter 1 and thiamine transporter 2 caused by uremia environment or a higher dose of thiamine may be needed. Further research is needed to confirm this. Moreover, the normal range for serum levels of folate is approximately 2.7-17ng/ml in the general population. However, in MHD patients, the serum levels of folate is at the low end of the normal range which has been founded in our study. After 96 weeks of folate supplementation, serum levels of folate were above the normal range, and this is exactly what our research needs to achieve.

Homocysteine is not only a uremia toxin but a biomarker of oxidative stress in patients with MHD. Many observational studies have suggested that elevated blood homocysteine levels are strongly associated with CI. Moreover, previous studies have found that there are many mechanisms that cause elevated homocysteine levels in MHD patients including deficiency of vitamins B, especially thiamine and folic acid. In the present study, blood homocysteine levels were significantly higher than the normal range in both groups at baseline, suggesting the presence of oxidative stress in patients of MHD with CI. Compared with baseline, homocysteine didn't decrease significantly (p=0.063) at week 96. Although, serum homocysteine level at week 96 in treatment group was lower than that in control group, we can't conclude thiamine combined with folic acid treatment improve MoCA scores dependent on decreasing homocysteine. A new study with larger sample size and longer follow-up time should be performed to clarify the role of serum homocysteine.

It is worth mentioning that the survival rate of MHD patients with CI was significantly lower than that of patients with normal cognitive function, suggesting that CI is a risk factor for death of MHD patients. Recent COGNITIVE-HD studies have also confirmed this phenomenon, therefore, it is urgent to find effective methods or measures to treat or improve the concurrent CI of MHD. In this study, Kaplan-Meier survival curve analysis indicated that the survival rate in treatment group was significantly higher than that in control group. The main cause of death in the two groups is cardiovascular and cerebrovascular events (9 cases, accounting for 75%), including 8 cases (88.9%) in the control group and 1 case (33.3%) in the treatment group. We believe that thiamine combined with folic acid treatment doesn't only improve MoCA scores but also decrease the risk of cardiovascular and cerebrovascular disease in patients undergoing hemodialysis.
Several limitations of our study should be considered. First, this study was not designed to use a blind method and placebo control. It may lead to the generation of psychological bias and influence the MoCA scores. Furthermore, the sample size is small, which will lead to insufficient grasp in statistics and may cause false negative results. Moreover, we only used MoCA score as the basis for judging cognitive functions, which was highly subjective and could not cover all the assessments of cognitive functions. Future studies need to include more scoring criteria such as neuropsychological battery of 10 tests\textsuperscript{[27]}, and even imaging tests such as functional magnetic resonance imaging\textsuperscript{[28]}, to accurately judge cognitive function. Finally, patients in treatment group were given two medicines, it was difficult to identify which one played a key role.

**Conclusion**

In conclusion, supplementation of thiamine (90mg/day) combined with folic acid (30mg/day) can improve MoCA scores and survival of MHD patients with CI.

**Abbreviations**

MoCA: Montreal Cognitive Assessment; ESRD: End stage renal disease; USRDS: United States Renal Data System; CI: Cognitive impairment; MHD: Maintenance hemodialysis; ROS: Reactive oxygen species; eNOS: endothelial nitric oxide synthase; BP: Blood pressure; CKD: Chronic kidney diseases

**Declarations**

**Ethical approval** This trial was approved by Renji Hospital Ethical Committee, Shanghai Jiao Tong University School of Medicine. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and and with the Helsinki Declaration of 1975 and its later amendments or comparable ethical standards.

**Trial registration** The study was registered on the Chinese Clinical Trial Registry in 2 August 2017 and URL of trial registry record is [http://www.chictr.org.cn/index.aspx](http://www.chictr.org.cn/index.aspx). Trial registration number is ChiCTR-IPR-17012210.

**Informed Consent** Written informed consent was obtained from all individual participants included in the study.

**Animal Rights** No animal studies were carried out by the authors for this article.

**Consent for publication**

Not applicable.

**Availability of data and materials**
The data analysed in the current study are available from the corresponding author on reasonable request. Raw data retained at the Clinical Center for Investigation, Renji Hospital (RJDBLK2020-03-N13001).

**Competing interests**

The authors declare that they have no competing interests

**Funding**

The present study was funded by 2017 Clinical research innovation training fund of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (grant number PYIII-17-028), 2019 Special fund for clinical medical research of Chinese medical association (grant number 18020030782) and 2019 Research seed fund training program of Renji Hospital, School of Medicine, Shanghai Jiao Tong University (grant number RJZZ19-004), as well as Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant (grant number 20172015).

**Authors' contributions**

RL, QW, SM, ZN and LG were responsible for study design. RL, YF, YZ, MC, JS, QL and HZ were responsible for data acquisition and coordinate. RL and SP were responsible for data analysis. As a professional neurologists, YL was responsible for cognitive function assessment. Each author contributed important intellectual content during article drafting. All authors have read and approved the manuscript.

**Acknowledgements**

We wish to thank other investigators including Hao Yan, Jiayi Yan, Li Ding, Jiahui Zhang, Haijiao Jin (Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China) and participants who contributed to the studies.

**Authors' information**

1. Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2. Clinical Center for Investigation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 3. Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

**References**

1. United States Renal Data System, USRDS 2018 Annual Data Report, Volume 2, End-Stage Renal Disease, Chapter1, Incidence, prevalence, patient characteristics, and treatment modalities, National
2. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385(9981): 1975-82.

3. Lu R, Kiernan MC, Murray A, Rosner MH, Ronco C. Kidney-brain crosstalk in the acute and chronic setting. Nature Reviews Nephrology. 2015;11(12):707-19.

4. Lu R, Xu C, Li Y, Yu L, Shao X, Xie K, et al. The Incidence Prognosis and Risk Factors of Cognitive Impairment in Maintenance Haemodialysis Patients. Blood Purification. 2019;47,:101-8.

5. Drew DA, Tighiouart H, Scott TM, Lou KV, Shaffi K, Weiner DE, et al. Cognitive performance before and during haemodialysis: A randomized cross-over trial. Nephron Clin Pract. 2013;124(3-4):151-8.

6. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc.2002;53:695-9.

7. Fujisaki K, Tsuruya K, Yamato M, Toyonaga J, Noguchi H, Nakano T, et al. Cerebral oxidative stress induces spatial working memory dysfunction in uraemic mice: neuroprotective effect of tempol. Nephrol Dial Transplant. 2014;29:529-38.

8. Calingasan NY, Chun WJ, Park LC, Uchida K, Gibson GE. Oxidative stress is associated with region-specific neuronal death during thiamine deficiency. J Neuropathol Exp Neurol.1999;58: 946-58.

9. Langlais PJ, Anderson G, Guo SX, Bondy SC. Increased cerebral free radical production during thiamine deficiency. Metab Brain Dis. 1997;12:137-43.

10. Stanger O. Physiology of folic acid in health and disease. Curr Drug Metab. 2002;3:211-23.

11. Gong YS, Hu K, Yang LQ, Guo J, Gao YQ, Song FL, et al. Comparative effects of EtOH consumption and thiamine deficiency on cognitive impairment, oxidative damage, and β-amyloid peptide overproduction in the brain. Free Radical Biology and Medicine. 2017;108:163-73.

12. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, et al. Folic Acid Therapy and Cardiovascular Disease in ESRD or Advanced Chronic Kidney Disease: A Meta-Analysis. Clin J Am Soc Nephrol. 2011;6:482-8.

13. Koh F, Charlton K, Walton K, McMahon AT. Role of Dietary Protein and Thiamine Intakes on Cognitive Function in Healthy Older People: A Systematic Review. Nutrients. 2015;7(4):2415-39.

14. Ford AH, Almeida OP. Effect of Vitamin B Supplementation on Cognitive Function in the Elderly: A Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(5):419-34.

15. Donnino MW, Vega J, Miller J, et al. Myths and misconceptions of Wernicke's encephalopathy: what every emergency physician should know. Ann Emerg Med. 2007;50:715-21.

16. Fuente­bella J, Kerner JA. Refeeding syndrome. Pediatr Clin North Am. 2009;56:1201-10.

17. Arnold L. Schultz, Samuel Natelson. Studies on the distribution and concentration of thiamine in blood and urine. Microchemical Journal. 1972, 17: 109-18.
18. Rosati R, Ma H, Cabelof DC. Folate and colorectal cancer in rodents: a model of DNA repair deficiency. J Oncol. 2012, 2012: 105949

19. Elens I, Dekeyster E, Moons L, D’Hooge R. Methotrexate Affects Cerebrospinal Fluid Folate and Tau Levels and Induces Late Cognitive Deficits in Mice. Neuroscience. 2019; 404:62-70.

20. Reidling JC, Nabokina SM, Balamurugan K, et al. Developmental maturation of intestinal and renal thiamin uptake: studies in wild-type and transgenic mice carrying human THTR-1 and 2 promoters. J Cell Physiol. 2006; 206: 371-7.

21. Ji Y, Lyu P, Jin W, Li X, Li X, Dong Y. Homocysteine: A modifiable culprit of cognitive impairment for us to conquer? J Neurol Sci. 2019;404:128-36.

22. Narayan SK, Saxby BK, Firbank MJ, et al. Plasma homocysteine and cognitive decline in older hypertensive subjects. Int Psychogeriatr. 2011; 23:1607-15.

23. A.Massy, I. Ceballos, B. Chadeaux-Vekemens, et al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney International. 2001;59(supplement 78):S243-S245.

24. A N Friedman, A G Bostom, J Selhub, A S Levey, I H Rosenberg. The kidney and homocysteine metabolism. J Am Soc Nephrol. 2001;12(10): 2181-9.

25. Himmelfarb J, McMonagle E. Manifestations of oxidant stress in uremia. Blood Purif. 2001;19: 200-5.

26. van Zwieten A, Wong G, Ruospo M, Palmer SC, Teixeira-Pinto A, Barulli MR, et al. Associations of Cognitive Function and Education Level With All-Cause Mortality in Adults on Hemodialysis: Findings From the COGNITIVE-HD Study. Am J Kidney Dis. 2019; 74(4): 452-2.

27. van Zwieten A, Wong G, Ruospo M, Palmer SC, Barulli MR, Iurillo A, et al. Prevalence and patterns of cognitive impairment in adult hemodialysis patients: the COGNITIVE-HD study. Nephrol Dial Transplant. 2018; 33:1197-206.

28. Zhang HY, Wang SJ, Liu B, Ma ZL, Yang M, Zhang ZJ, et al. Resting brain connectivity: changes during the progress of Alzheimer disease. Radiology. 2010; 256(2):598-606.

Figures
Figure 1

The Kaplan-Meier patient survival analysis between the treatment group and the control group ($p = 0.048$)

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Checklist.pdf
- SupplementalInformation.pdf